Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

Carcinogenesis

Volumn 25, Issue 12, 2004, Pages 2451-2458

  Fujieda, Masaki ^a   Yamazaki, Hiroshi ^a   Saito, Tetsuya ^a   Kiyotani, Kazuma ^a   Gyamfi, Maxwell Afari ^a   Sakurai, Masaharu ^b   Dosaka Akita, Hirotoshi ^c   Sawamura, Yuichi ^d   Yokota, Jun ^e   Kunitoh, Hideo ^f   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Maruyama Clinic   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; HUMAN; JAPAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 10344238546     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh258     Document Type: Article

References (53)

1. Yamano,S., Tatsuno,J. and Gonzalez,F.J. (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322-1329.
2. Nakajima,M., Yamamoto,T., Nunoya,K. et al. (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos., 24, 1212-1217.
3. Nunoya,K., Yokoi,T., Kimura,K. et al. (1996) (+)-cis 3,5-Dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J. Pharmacol. Exp. Ther., 277, 768-774.
4. Komatsu,T., Yamazaki,H., Shimada,N., Nakajima,M. and Yokoi,T. (2000) Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos., 28, 1457-1463.
5. Pelkonen,O., Rautio,A., Raunio,H. and Pasanen,M. (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology, 144, 139-147.
6. Kharasch,E.D., Hankins,D.C. and Thummel,K.E. (1995) Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology, 82, 689-699.
7. Sadeque,A.J.M., Fisher,M.B., Korzekwa,K.R., Gonzalez,F.J. and Rettie,A.E. (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther., 283 698-703.
8. Crespi,C.L., Penman,B.W., Gelboin,H.V. and Gonzalez,F.J. (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis, 12, 1197-1201.
9. Fujita,K. and Kamataki,T. (2001) Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen., 38, 339-346.
10. Rautio,A., Kraul,H., Kojo,A., Salmela,E. and Pelkonen,O. (1992) Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics, 2, 227-233.
11. Iscan,M., Rostami,H., Guray,T., Pelkonen,O. and Rautio,A. (1994) Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur. J. Clin. Pharmacol., 47, 315-318.
12. Nelson,D.R., Koymans,L., Kamataki,T. et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
13. Oscarson,M., Gullsten,H., Rautio,A., Bernal,M.L., Sinues,B., Dahl,M.-L., Stengard,J.H., Pelkonen,O., Raunio,H. and Ingelman-Sundberg,M. (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett., 438, 201-205.
14. Oscarson,M., McLellan,R.A., Gullsten,H., Agundez,J.A.G., Benitez,J., Rautio,A., Raunio,H., Pelkonen,O. and Ingelman-Sundberg,M. (1999) Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett. 460, 321-327.
15. Kitagawa,K., Kunugita,N., Kitagawa,M. and Kawamoto,T. (2001) CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem., 21, 17830-17835.
16. Kiyotani,K., Yamazaki,H., Fujieda,M., Daigo,S., Satarug,S., Ujjin,P. and Kamataki,T. (2002) Novel mutations of the CYP2A6 gene in a Thai population with capacity of coumarin 7-hydroxylation. Drug Metab. Pharmacokinet., 17, 161-163.
17. Kiyotani,K., Fujieda,M., Yamazaki,H., Shimada,T., Guengerich,F.P., Parkinson,A., Nakagawa,K., Ishizaki,T. and Kamataki,T. (2002) Twenty one novel single polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab. Pharmacokinet., 17 453-458.
18. Oscarson,M., McLellan,R.A., Asp,V., Ledesma,M., Ruiz,M.L., Sinues,B., Rautio,A. and Ingelman-Sundberg,M. (2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat., 20, 275-283.
19. Nunoya,K., Yokoi,T., Kimura,K. et al. (1998) A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+ -cis 3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics, 8, 239-249.
20. Ariyoshi,N., Sekine,H., Saito,K. and Kamataki,T. (2002) Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics, 12, 501-504.
21. Ariyoshi,N., Sawamura,Y. and Kamataki,T. (2001) A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem. Biophys. Res. Commun., 281, 810-814.
22. Daigo,S., Takahashi,Y., Fujieda,M. et al. (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics, 12, 299-306.
23. Kiyotani,K., Yamazaki,H., Fujieda,M. et al. (2003) Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics, 13, 689-695.
24. Xu,C., Rao,Y.S., Xu,B., Hoffman,E., Jones,J., Sellers,E.M. and Tydale,R.F. (2002) An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 290, 318-324.
25. Zimmermann,F.K. and Roberts,J.J. (1971) Genetic aspects of carcinogenesis. Biochem. Pharmacol., 20, 985-995.
26. Perera,F.R. (1997) Environment and cancer: who are susceptible? Science, 278, 1068-1073.
27. London,S.J., Idle,J.R., Daly,A.K. and Coetzee,G.A. (1999) Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet, 353, 898-899.
28. Miyamoto,M., Umetsu,Y., Dosaka-Akita,H., Sawamura,Y., Yokota,J., Kunitoh,H., Nemoto,N., Sato,K., Ariyoshi,N. and Kamataki,T. (1999) CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun., 261, 658-660.
29. Loriot,M-A., Rebuissou,S., Oscarson,M., Cenee,S., Miyamoto,M., Ariyoshi,N., Kamataki,T., Hemon,D., Beaune,P. and Stucker,I. (2001) Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics, 11, 39-44.
30. Tan,W., Chen,G.-F., Xing,D.-Y., Song,C.-Y., Kadlubar,F.F. and Lin,D.-X. (2001) Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer, 95, 96-101.
31. Ariyoshi,N., Miyamoto,M., Umetsu,Y., Kunitoh,H., Dosaka-Akita,H., Sawamura,Y., Yokota,J., Nemoto,N., Sato,K. and Kamataki,T. (2002) Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev., 11, 890-894.
32. Wang,H., Tan,W., Hao,B., Miao,X., Zhou,G., He,F. and Lin,D. (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res., 63, 8057-8061.
33. Takeuchi,H., Saoo,K., Yokohira,M., Ikeda,M., Maeta,H., Miyazaki,M., Yamazaki,H., Kamataki,T. and Imaida,K. (2003) Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res., 63, 7581-7583.
34. Shimosato,Y. (2000) Pathology: revised classification of epithelial tumors of the lung (WHO/IASLC). In Hansen,H.H. (ed.), Textbook of Lung Cancer. Martin Dunitz, London, pp. 125-140.
35. Sambrook,J., Fritsch,E.F. and Maniatis,T. (1989) Molecular cloning. In A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press, New York.
36. Ariyoshi,N., Takahashi,Y., Miyamoto,M. et al. (2000) Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics, 10, 687-693.
37. Wynder,E.L. and Hoffmann,D. (1994) Smoking and lung cancer: scientific challenges and opportunities. Cancer Res., 54, 5284-5295.
38. Le Marchand,L., Sivaraman,L., Pierce,L., Seifried,A., Lum,A., Wilkens,L.R. and Lau,A.F. (1998) Association of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res., 58, 4858-4863.
39. Oscarson,M., McLellan,R.A., Gullsten,H. et al. (1999) Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett., 448, 105-110.
40. Yoshida,R., Nakajima,M., Watanabe,Y., Kwon,J.-T. and Yokoi,T. (2002) Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol., 54, 511-517.
41. Tyndale,R.F. and Sellers,E.M. (2001) Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab. Dispos., 29, 548-552.
42. Tyndale,R.F. and Sellers,E.M. (2002) Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther. Drug Monit., 24, 163-171.
43. Sellers,E.M., Tyndale,R.F. and Fernandes,L.C. (2003) Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov. Today, 8, 487-493.
44. Sellers,E.M., Ramamoorthy,Y., Zeman,M.V., Djordjevic,M.V. and Tyndale,R.F. (2003) The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res., 5, 891-899.
45. Fernandez-Salguero,P., Hoffman,S.M., Cholerton,S. et al. (1995) A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet., 57, 651-660.
46. Pianezza,M.L., Sellers,E.M. and Tyndale,R.F. (1998) Nicotine metabolism defect reduces smoking. Nature, 393, 750.
47. Saarikoski,S.T., Sata,F., Husgafvel-Pursiainen,K., Rautalahti,M., Haukka,J., Impivaara,O., Jarvisalo,J., Vainio,H. and Hirvonen,A. (2000) CYP2D6 ultrarapid metabolizer genotypes as a potential modifier of smoking behaviour. Pharmacogenetics, 10, 5-10.
48. Carmella,S.G., Borukhova,A., Desai,D. and Hecht,S.S. (1997) Evidence for endogenous formation of tobacco-specific nitrosamines in rats treated with tobacco alkaloids and sodium nitrite. Carcinogenesis 18, 587-592.
49. Smith,T.J., Guo,Z., Gonzalez,F.J., Guengerich,F.P., Stoner,G.D. and Yang,C.S. (1980) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res., 52, 1757-1763.
50. Smith,T.J., Stoner,G.D. and Yang,C.S. (1980) Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res., 55, 5566-5573.
51. Fujieda,M., Yamazaki,H., Kiyotani,K., Muroi,A., Kunitoh,H., Dosaka-Akita,H., Sawamura,Y. and Kamataki,T. (2003) Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metab. Pharmacokinet., 18, 86-90.
52. McManus,M.E., Burgess,W.M., Veronese,M.E., Huggett,A., Quattrochi,L.C. and Tukey,R.H. (1990) Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res., 50, 3367-3376.
53. Shimada,T., Yun,C.H., Yamazaki,H., Gautier,J.C., Beaune,P.H. and Guengerich,F.P. (1992) Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol., 41, 856-864.